Ignite Creation Date:
2025-12-24 @ 11:10 PM
Ignite Modification Date:
2025-12-31 @ 7:30 AM
Study NCT ID:
NCT01515969
Status:
TERMINATED
Last Update Posted:
2016-07-12
First Post:
2011-12-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)
Sponsor:
Heather Wakelee
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
IRB-21659
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None